IMS Generic Planning is the one vital strategy and planning tool for accurately assessing future opportunities in the generic pharmaceutical market.
Generic Planning helps you to identify and plan for generic opportunities and challenges by:
- Analyzing sales and trends of products or molecules losing protection in the next 11 years
- Reviewing and evaluating pharmaceutical patent families affecting molecules
Contents
- Contains data on marketed molecules that will lose protection over the next 11 years.
- Measures accurate and reliable IMS Health audited year-end sales data in USD and Kilograms.
- Includes four years compound growth in US dollars (data at December).
- Searches by products, molecules, countries, anatomical therapy classes, corporations, patent expiry years and dates, international products, form codes (physical form of a drug).
- Features patent extension and exclusivity information:
- including SPC/CCP expiry dates, Data Exclusivity Expiry dates, Marketing Exclusivity Expiry dates, Marketing Authorization dates and New date of Product Protection Expiry.
and identifies the various patents (i.e. composition, process, product patents) that apply to a particular molecule.
Key Benefits
- Accurately predict when a product or a molecule will face protection expiry
- Identify opportunities within a profitable niche market
- Review sales growth of current blockbusters or drugs in specialized therapy areas or specific physical forms
- Understand the competition for your selected molecule
Next Steps
